Combined pitavastatin and capmatinib inhibits tumor growth though completed shutdown of MET signal. Combined pitavastatin and capmatinib inhibits tumor growth though completed shutdown of MET signal

To reveal the function of pitavastatin in cancer, we performed several experiments. In the present study, we show that pitavastatin inhibits the tumor growth through the inactivation of ERK and AKT signals by MET immaturation, and combination of pitavastatin and capmatinib, a MET inhibitor, might be useful cancer therapy in OSCC and ESCC. It could be reduced the dose of pitavastatin by using this combination therapy, resulting in decreasing the risk of adverse events such as myopathy. Taken together, the mevalonate pathway regulates the processes of MET maturation and promotes the cell growth in cancer. Moreover, the expression of GGPS1, an enzyme that synthesizes geranylgeranyl pyrophosphate (GGPP) from farnesyl pyrophosphate (FPP), associates with the sensitivity of pitavastatin, suggesting that GGPS1 could be a biomarker in cancer therapy with pitavastatin. Identification of the function of pitavastatin in oral and esophageal squamous cell carcinoma. Overall design: Extraction of difference of gene expression level between control and treatment of pitavastatin in HOC313-LM, KYSE150 and KYSE200. Also, extraction of difference of gene expression level between transfection of si-NC and si-GGPS1 in HOC313-LM.